Infectious Disease · 1984
Marshall & Warren: Helicobacter pylori causes peptic ulcer disease
By the early 1980s, the management of peptic ulcer disease had reached a stable, if unsatisfying, equilibrium. H2 blockers suppressed acid and healed ulcers, but recurrence after stopping treatment was the rule rather than the exception. The prevailing model attributed ulcers to excessive acid secretion compounded by stress, diet, and a constitutionally vulnerable mucosa. Bacteria were not part of the picture; the conventional view held that the stomach's acid environment was simply incompatible with microbial colonization.
Robin Warren, a pathologist at Royal Perth Hospital in Western Australia, had been observing a curved bacillus on gastric antral biopsies since 1979 and noted a consistent association with active chronic gastritis. When Barry Marshall joined the hospital as a gastroenterology registrar in 1981, Warren recruited him to investigate further. Marshall designed a prospective series, enrolled 100 consecutive patients undergoing upper endoscopy, and obtained antral biopsies for both histology and culture. The results, published in the Lancet on June 16, 1984, showed the organism in virtually all patients with active chronic gastritis and in the great majority with duodenal ulcer.
The reception was hostile. Gastroenterologists and industry scientists with stakes in acid suppression therapy challenged the methodology, questioned whether the bacterium was a commensal passenger rather than a pathogen, and pointed to the absence of a formal animal model fulfilling Koch's postulates. Marshall addressed the criticism directly. In mid-1984, he drank a broth culture of H. pylori, developed nausea and epigastric pain within days, and underwent endoscopy that confirmed acute gastritis with the organism on biopsy. He then treated himself with tinidazole and bismuth. The experiment was self-reported, not controlled, but it produced documented histological evidence and satisfied modified Koch's postulates under circumstances no institutional review board would have approved in a formal trial.
Wider acceptance accumulated through the late 1980s as independent groups replicated the association, eradication trials showed ulcer recurrence fell to near zero after H. pylori clearance, and cohort data linked the organism to gastric adenocarcinoma and MALT lymphoma. By the early 1990s, testing and treating H. pylori had entered mainstream guidelines. The Nobel Prize in Physiology or Medicine was awarded to Marshall and Warren in 2005; the Nobel Committee's citation explicitly noted the finding had been unexpected and that the medical establishment had resisted it for years.
Triple therapy combining a proton pump inhibitor with clarithromycin and amoxicillin or metronidazole eradicates H. pylori in the majority of cases and reduces ulcer recurrence to single-digit percentages compared with the near-certain relapse seen with acid suppression alone. The practical consequence was that a condition managed chronically with daily medication became one curable in two weeks. Antibiotic resistance has complicated first-line regimens in parts of the world with high clarithromycin resistance rates, and quadruple bismuth-based regimens are now preferred in those settings, but the basic principle Marshall and Warren established remains the foundation of peptic ulcer management.
Key People
- Barry Marshall — Perth gastroenterology trainee who designed the clinical series and self-experimented
- Robin Warren — Perth pathologist who first identified the bacillus on antral biopsies in 1979
- David Graham — Houston gastroenterologist whose eradication trials helped establish treatment efficacy
Lancet, 1984
Related landmarks
- 1981 · First report of AIDS (Pneumocystis pneumonia cluster) (Infectious Disease)
- 1987 · AZT (Zidovudine) Trial for AIDS (Infectious Disease)
- 1987 · Haemophilus influenzae type b (Hib) conjugate vaccine (Infectious Disease)
- 1996 · Highly Active Antiretroviral Therapy (HAART) and the Vancouver protease-inhibitor combination era (Infectious Disease)